Literature DB >> 17127787

Acute myeloid leukemia with severe aplastic anemia following immunosuppressive therapy.

Sameer Bakhshi1, Ajay Gupta, Lalit Kumar.   

Abstract

Severe aplastic anemia (AA) is a life-threatening condition wherein bone marrow transplantation (BMT) is the therapy of choice in a young patient who has a matched sibling donor. Here, we report an 11-year-old boy with severe AA who was referred for BMT late in its course when he had developed acute myeloid leukemia following two courses of immunosuppressive therapy with antithymocyte globulin and cyclosporin. He was then treated with induction therapy using cytosine arabinoside and daunomycin for acute myeloid leukemia, but he succumbed due to infection and refractory leukemia. We discuss the relevance of early referral for BMT in severe AA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17127787     DOI: 10.1007/bf02758313

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  14 in total

1.  Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation.

Authors:  S Kojima; K Horibe; J Inaba; A Yoshimi; Y Takahashi; K Kudo; K Kato; T Matsuyama
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

2.  Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anaemia.

Authors:  S B Killick; N Win; J C Marsh; T Kaye; A Yandle; C Humphries; S M Knowles; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

Review 3.  Aplastic anaemia.

Authors:  Robert A Brodsky; Richard J Jones
Journal:  Lancet       Date:  2005 May 7-13       Impact factor: 79.321

Review 4.  Current status of allogeneic bone marrow transplantation in acquired aplastic anemia.

Authors:  M M Horowitz
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

Review 5.  Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia.

Authors:  D A Margolis; J T Casper
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

Review 6.  Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience.

Authors:  A Bacigalupo; R Brand; R Oneto; B Bruno; G Socié; J Passweg; A Locasciulli; M T Van Lint; A Tichelli; S McCann; J Marsh; P Ljungman; J Hows; P Marin; H Schrezenmeier
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

7.  Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia.

Authors:  A Ohara; S Kojima; N Hamajima; M Tsuchida; S Imashuku; S Ohta; H Sasaki; J Okamura; K Sugita; H Kigasawa; Y Kiriyama; J Akatsuka; I Tsukimoto
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

Review 8.  Management of acquired aplastic anaemia.

Authors:  Judith C W Marsh
Journal:  Blood Rev       Date:  2005-05       Impact factor: 8.250

9.  [Acute monocytic leukemia following anti-lymphocyte immunoglobulin treatment in a patient with severe aplastic anemia].

Authors:  Y Ohbayashi; M Nagai; K Sasaki; M Murata; T Tasaka; Y Kubota; K Ikeda; J Takahara; S Irino
Journal:  Rinsho Ketsueki       Date:  1993-05

10.  Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group.

Authors:  M Führer; S Burdach; W Ebell; H Gadner; R Haas; J Harbott; G Janka-Schaub; T Klingebiel; B Kremens; C Niemeyer; U Rampf; A Reiter; J Ritter; A Schulz; U Walther; C Zeidler; C Bender-Götze
Journal:  Klin Padiatr       Date:  1998 Jul-Aug       Impact factor: 1.349

View more
  1 in total

1.  A novel autologous stem cell procedure for the treatment of aplastic anaemia using reprogrammed mature adult cells: a pilot study.

Authors:  Ilham Saleh Abuljadayel; Dipika Mohanty; Rajendar K Suri
Journal:  Indian J Med Res       Date:  2012-06       Impact factor: 2.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.